Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1387357

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1387357

Antihypertensive Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Antihypertensive Drug Trends and Forecast

The future of the global antihypertensive drug market looks promising with opportunities in the retail pharmacy, hospital pharmacy, and e-commerce markets. The global antihypertensive drug market is expected to grow with a CAGR of 4.7% from 2024 to 2030. The major drivers for this market are growing incidence of hypertension, rising efforts and initiatives by both private and government organizations, and increasing awareness of hypertension.

A more than 150-page report is developed to help in your business decisions.

Antihypertensive Drug by Segment

The study includes a forecast for the global antihypertensive drug by therapeutic class, distribution channel, and region.

Antihypertensive Drug Market by Therapeutic Class [Shipment Analysis by Value from 2018 to 2030]:

  • Diuretics
  • ACE Inhibitors
  • Calcium Channel Blockers
  • Vasodilators
  • Beta-Adrenergic Blockers
  • Others

Antihypertensive Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-Commerce
  • Others

Antihypertensive Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Antihypertensive Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antihypertensive drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antihypertensive drug companies profiled in this report include-

  • Lupin
  • Boehringer Ingelheim International
  • Sun PharmACEutical Industries
  • Astrazeneca
  • Novartis
  • SANOFI
  • Merck

Antihypertensive Drug Market Insights

Lucintel forecasts that calcium channel blocker will remain the largest segment over the forecast period due to its affordability, high efficacy, and lesser side effects as compare to other therapeutic classes.

Within this market, hospital will remain the largest segment due to increase in number of hospitals worldwide.

North America will remain the largest region over the forecast period due to surge in incidence of hypertension and rise in geriatric population.

Features of the Global Antihypertensive Drug Market

Market Size Estimates: Antihypertensive drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antihypertensive drug market size by therapeutic class, distribution channel, and region in terms of value ($B).

Regional Analysis: Antihypertensive drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapeutic classes, distribution channels, and regions for the antihypertensive drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antihypertensive drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for antihypertensive drug market?

Answer: The global antihypertensive drug market is expected to grow with a CAGR of 4.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the antihypertensive drug market?

Answer: The major drivers for this market are growing incidence of hypertension, rising efforts and initiatives by both private and government organizations, and increasing awareness of hypertension.

Q3. What are the major segments for antihypertensive drug market?

Answer: The future of the antihypertensive drug market looks promising with opportunities in the retail pharmacy, hospital pharmacy, and e-commerce markets.

Q4. Who are the key antihypertensive drug market companies?

Answer: Some of the key antihypertensive drug companies are as follows:

  • Lupin
  • Boehringer Ingelheim International
  • Sun PharmACEutical Industries
  • Astrazeneca
  • Novartis
  • SANOFI
  • Merck

Q5. Which antihypertensive drug market segment will be the largest in future?

Answer: Lucintel forecasts that calcium channel blocker will remain the largest segment over the forecast period due to its affordability, high efficacy, and lesser side effects as compare to other therapeutic classes.

Q6. In antihypertensive drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to surge in incidence of hypertension and rise in geriatric population.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the antihypertensive drug market by therapeutic class (diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others), distribution channel (retail pharmacy, hospital pharmacy, e-commerce, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pACE and why?
  • Q.3. Which region will grow at a faster pACE and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antihypertensive Drug Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Antihypertensive Drug Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Antihypertensive Drug Market by Therapeutic Class
    • 3.3.1: Diuretics
    • 3.3.2: ACE Inhibitors
    • 3.3.3: Calcium Channel Blockers
    • 3.3.4: Vasodilators
    • 3.3.5: Beta-adrenergic Blockers
    • 3.3.6: Others
  • 3.4: Global Antihypertensive Drug Market by Distribution Channel
    • 3.4.1: Retail Pharmacy
    • 3.4.2: Hospital Pharmacy
    • 3.4.3: E-commerce
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Antihypertensive Drug Market by Region
  • 4.2: North American Antihypertensive Drug Market
    • 4.2.2: North American Antihypertensive Drug Market by Distribution Channel: Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others
  • 4.3: European Antihypertensive Drug Market
    • 4.3.1: European Antihypertensive Drug Market by Therapeutic Class: Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others
    • 4.3.2: European Antihypertensive Drug Market by Distribution Channel: Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others
  • 4.4: APAC Antihypertensive Drug Market
    • 4.4.1: APAC Antihypertensive Drug Market by Therapeutic Class: Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others
    • 4.4.2: APAC Antihypertensive Drug Market by Distribution Channel: Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others
  • 4.5: ROW Antihypertensive Drug Market
    • 4.5.1: ROW Antihypertensive Drug Market by Therapeutic Class: Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others
    • 4.5.2: ROW Antihypertensive Drug Market by Distribution Channel: Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Antihypertensive Drug Market by Therapeutic Class
    • 6.1.2: Growth Opportunities for the Global Antihypertensive Drug Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Antihypertensive Drug Market by Region
  • 6.2: Emerging Trends in the Global Antihypertensive Drug Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Antihypertensive Drug Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antihypertensive Drug Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Lupin
  • 7.2: Boehringer Ingelheim International
  • 7.3: Sun PharmACEutical Industries
  • 7.4: AstraZeneca
  • 7.5: Novartis
  • 7.6: SANOFI
  • 7.7: Merck
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!